AMNOG Benefit Dossiers According to § 35a SGB V

Germany has gone through a major regulatory change.

 

AMNOG Benefit Dossiers according to § 35a SGB V

The Pharmaceutical Market Restructuring Act (AMNOG) and the resulting requirements for benefit assessment according to § 35a SGB V have changed the conditions of market access and the pricing of pharmaceuticals fundamentally in Germany. This new regulation applies to newly approved and already existing pharmaceuticals.

Our Services:

We develop entire Benefit Dossiers or specific parts for an existing Benefit Dossier.
We offer strategic consulting and support in developing a Benefit Dossier, as well as professional review of existing Benefit Dossiers.